Our findings suggest that ADT-induced CHRM4 may activate AKT/MYCN signaling to induce IFNA17 secretion and upregulate immune checkpoints in the TME to drive potential immunosuppressive responses, leading to NED and metastasis in prostate cancer. This evidence concerns the gene MYCN and Familial prostate cancer.